Welcome to our dedicated page for Meiragtx Holdings Plc SEC filings (Ticker: MGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MeiraGTx Holdings plc (Nasdaq: MGTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage genetic medicines company with programs in ophthalmology, Parkinson’s disease and radiation-induced xerostomia, MeiraGTx uses SEC reports to communicate material events, financial results and key collaboration agreements to investors.
Among the filings available are current reports on Form 8-K, which MeiraGTx has used to announce quarterly financial and operational results, strategic collaborations and regulatory milestones. For example, the company has filed 8-Ks describing its strategic collaboration and license agreement with Eli Lilly and Company in ophthalmology, its broad collaboration with Hologen Limited to form Hologen Neuro AI Ltd, and the receipt of foreign direct investment clearances related to that collaboration. Other 8-Ks reference the release of financial results for specific quarters.
In addition to current reports, investors can use this page to locate MeiraGTx’s periodic filings, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, when available. These documents typically contain detailed discussions of the company’s clinical pipeline, including programs like AAV-AIPL1, AAV2-hAQP1 and AAV-GAD, as well as risk factors, management’s discussion and analysis, and information on its manufacturing infrastructure and collaborations.
Stock Titan enhances access to these filings by providing real-time updates from the SEC’s EDGAR system and AI-powered summaries that explain the key points in plain language. Users can quickly see which filings relate to clinical data, regulatory designations, strategic partnerships or financing. The filings page also surfaces information on items such as material definitive agreements, like the collaboration and license agreement with Eli Lilly, and other disclosures that may affect MeiraGTx’s development plans and capital position.
For those tracking MeiraGTx’s progress in genetic medicine, this page offers a structured view of how the company reports its activities to regulators and the market, from clinical and regulatory milestones to manufacturing and partnership developments.
MeiraGTx Holdings plc chief medical officer Robert K. Zeldin reported equity award activity involving restricted share units and ordinary shares. On
MeiraGTx Holdings plc reported that its General Counsel and Secretary, Robert J. Wollin, acquired ordinary shares through the vesting of restricted share units. On February 21, 2026, one-quarter of a prior grant of 11,250 restricted share units vested and converted into 11,250 ordinary shares at no exercise price.
Following the conversion, 5,949 ordinary shares were withheld to cover tax obligations associated with the vesting, at a price of $7.45 per share. After these transactions, Wollin held 57,377 ordinary shares directly. These movements reflect routine equity compensation vesting and related tax withholding rather than open‑market trading.
MeiraGTx Holdings plc Chief Development Officer Stuart Naylor reported equity award activity related to previously granted restricted share units. On February 21, 2026, one-quarter of his restricted share units granted on February 21, 2023 vested, resulting in 25,000 restricted share units converting into 25,000 ordinary shares, with no exercise price. Following this vesting and conversion, his direct holdings briefly totaled 707,916 ordinary shares. To cover tax obligations on the vesting, 11,750 ordinary shares were withheld and disposed of at $7.45 per share, a tax-withholding disposition rather than an open-market sale, leaving him with 696,166 ordinary shares held directly.
MeiraGTx Holdings plc CFO & COO Richard Giroux reported equity award activity involving restricted share units and ordinary shares. On February 21, 2026, one-quarter of previously granted restricted share units vested, converting 60,000 restricted share units into 60,000 ordinary shares at a stated price of $0.00 per share. To cover taxes due upon vesting, 31,726 ordinary shares were withheld at $7.45 per share as a tax-withholding disposition. Following these transactions, Giroux directly held 1,027,530 ordinary shares, with additional indirect holdings of 5,152 ordinary shares held by his spouse and 85,000 ordinary shares held by Aigle Healthcare Partners III LLC.
MeiraGTx Holdings plc President and CEO Alexandria Forbes reported equity award activity involving restricted share units and ordinary shares. On February 21, 2026, 62,500 restricted share units vested and were converted into 62,500 ordinary shares at a stated price of
MeiraGTx Holdings plc received an updated ownership report from a Prosight investment group on Ordinary Shares. The group, including Prosight Management, Prosight Fund, Prosight Plus Fund, Prosight Partners and W. Lawrence Hawkins, reports beneficial ownership of 3,211,788 Ordinary Shares, or 4.0% of the company, as of the event date. This percentage is calculated using 80,490,889 Ordinary Shares outstanding as of October 28, 2025. The reporting persons certify the shares are not held to change or influence control of MeiraGTx and are reported on a passive Schedule 13G/A basis.
MeiraGTx Holdings plc disclosed that investment firm Rubric Capital Management LP and David Rosen have filed a Schedule 13G reporting beneficial ownership of 6,175,331 Ordinary Shares, equal to 7.90% of the company’s ordinary shares outstanding as of year-end 2025.
The filing shows Rubric Capital and Rosen share both voting and dispositive power over these shares, which are held through Rubric-managed funds, including Rubric Capital Master Fund LP. They state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of MeiraGTx.
MeiraGTx Holdings plc’s Chief Medical Officer, Robert K. Zeldin, reported equity compensation activity on January 17, 2026. One-half of a prior grant of restricted share units vested, resulting in 35,000 restricted share units converting into the same number of ordinary shares at an exercise price of $0.
To cover taxes due on this vesting, 13,951 ordinary shares were automatically withheld and disposed of at a price of $7.42 per share. After these transactions, Zeldin directly beneficially owned 168,340 ordinary shares of MeiraGTx. The filing indicates these are routine equity award vesting and tax-withholding events rather than open-market purchases or discretionary sales.
MeiraGTx Holdings plc reported an insider equity transaction for its General Counsel and Secretary, Robert J. Wollin. On January 17, 2026, one-half of a prior award of restricted share units vested, resulting in 50,000 ordinary shares being issued upon conversion of the vested units at an exercise price of $0 per share. In a related transaction, 27,206 ordinary shares were withheld at $7.42 per share to cover taxes due on the vesting. Following these transactions, Wollin directly owned 52,076 ordinary shares of MeiraGTx.
MeiraGTx Holdings plc Chief Development Officer Stuart Naylor reported equity compensation activity on January 17, 2026. One-half of a prior grant of restricted share units vested, converting 75,000 restricted share units into 75,000 ordinary shares at an exercise price of $0. To cover taxes due upon vesting, 35,250 ordinary shares were withheld at a value of $7.42 per share. After these transactions, Naylor directly owned 682,916 ordinary shares of MeiraGTx and continued to hold 75,000 restricted share units that remain outstanding.